Low molecular weight heparins differ substantially: Impact on developing biosimilar drugs

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 3, 2011, Pages 322-327

  Walenga, Jeanine M ^a   Jackson, Craig M ^b   Kessler, Craig M ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Coagulation Diagnostics ^*  (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biosimilar; generic; low molecular weight heparin; safety; thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; GENERIC DRUG; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ANTICOAGULATION; ARTICLE; COMPARATIVE STUDY; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; ENDOTHELIUM CELL; FIBRINOLYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; IMMUNE RESPONSE; IMMUNOGENICITY; POLYPHARMACY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTIGEN-ANTIBODY REACTIONS; DRUG APPROVAL; DRUG DESIGN; DRUGS, GENERIC; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PHARMACEUTICAL PREPARATIONS; THERAPEUTIC EQUIVALENCY; THROMBOEMBOLISM; UNITED STATES;

EID: 79953651951     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1274515     Document Type: Article

References (58)

1. Engelberg A B., Kesselheim A S., Avorn J. Balancing innovation, access, and profitsmarket exclusivity for biologics. N Engl J Med 2009 361 20 1917-1919
2. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002 346 7 469-475 (Pubitemid 34441737)
3. Rosendaal F R., Nieuwenhuis H K., van den Berg H M. et al, Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993 81 8 2180-2186 (Pubitemid 23106736)
4. Li J L., Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001 98 12 3241-3248
5. Harenberg J, Kakkar A, Bergqvist D et al, Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost 2009 7 7 1222-1225
6. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins. European Medicines Agency, London, March 19, 2009, EMEA/CHMP/BMWP/118264/2007, 2007. Available at: http://www.emea.europa.eu/ pdfs/human/biosimilar/11826407enfin.pdf Accessed September 6, 2009
7. Casu B, Torri G. Structural characterization of low molecular weight heparins. Semin Thromb Hemost 1999 25 Suppl 3 17-25 (Pubitemid 29517029)
8. Jeske W P., Walenga J M., Hoppensteadt D A. et al. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 2008 34 1 74-85 (Pubitemid 351640883)
9. Jeske W P., Walenga J M., Fareed J. Differentiating between the low-molecular-weight heparins used for venous thromboembolism treatment and prophylaxis. Thrombosis Clinic 2008 2 8-21
10. Nicolau J C., Cohen M, Montalescot G. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes. J Cardiovasc Pharmacol 2009 53 6 440-445
11. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga J M. Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996 22 Suppl 1 77-91 (Pubitemid 26268428)
12. Oosta G M., Gardner W T., Beeler D L., Rosenberg R D. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A 1981 78 2 829-833 (Pubitemid 11159519)
13. Lindahl U, Thunberg L, Bäckström G, Riesenfeld J, Nordling K, Björk I. Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem 1984 259 20 12368-12376 (Pubitemid 15204810)
14. Ofosu F A., Danishefsky I, Hirsh J. Heparin and related polysaccharides. Structure and activities. Ann N Y Acad Sci 1989 556 1-501
15. Rosenberg R D., Bauer K A. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman R W. Hirsh J Marder V J. et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, PA JB Lippincott 1994 837-860
16. Tollefsen D M., Majerus D W., Blank M K. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982 257 5 2162-2169 (Pubitemid 12069768)
17. Tobu M, Ma Q, Iqbal O et al. Comparative tissue factor pathway inhibitor release potential of heparins. Clin Appl Thromb Hemost 2005 11 1 37-47 (Pubitemid 40194196)
18. Friedel H A., Balfour J A. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 1994 48 4 638-660
19. Montalescot G, Collet J P., Lison L et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000 36 1 110-114 (Pubitemid 30466120)
20. Salzman E W., Rosenberg R D., Smith M H., Lindon J N., Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980 65 1 64-73 (Pubitemid 10214332)
21. Eika C. Inhibition of thrombin induced aggregation of human platelets by heparin. Scand J Haematol 1971 8 3 216-222
22. Guerrini M, Guglieri S, Casu B et al. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue. J Biol Chem 2008 283 39 26662-26675
23. Capila I, Linhardt R J. Heparin-protein interactions. Angew Chem Int Ed Engl 2002 41 3 391-412
24. Houbouyan L, Padilla A, Gray E, Longstaff C, Barrowcliffe T W. Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and clotting methods. Blood Coagul Fibrinolysis 1996 7 1 24-30 (Pubitemid 26106168)
25. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 3, Suppl 188S-203S (Pubitemid 39297954)
26. Collignon F, Frydman A, Caplain H et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparinsdalteparin, enoxaparin and nadroparinadministered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995 73 4 630-640
27. Eriksson B I., Söderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995 73 3 398-401
28. Andrassy K, Eschenfelder V. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 1996 81 2, Suppl S29-S38 (Pubitemid 26076657)
29. Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997 77 2 317-322 (Pubitemid 27084923)
30. Nugent M A. Heparin sequencing brings structure to the function of complex oligosaccharides. Proc Natl Acad Sci U S A 2000 97 19 10301-10303
31. Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 2001 11 2 75-82 (Pubitemid 32144754)
32. Oelschläger C, Römisch J, Staubitz A et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002 99 11 4015-4020 (Pubitemid 35332042)
33. Elsayed E, Becker R C. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis 2003 15 1 11-18 (Pubitemid 37376350)
34. Rao N V., Kennedy T P., Rao G, Ky N, Hoidal J R. Sulfated polysaccharides prevent human leukocyte elastase-induced acute lung injury and emphysema in hamsters. Am Rev Respir Dis 1990 142 2 407-412 (Pubitemid 20235954)
35. Thourani V H., Brarr S S., Kennedy T P. et al. Nonanticoagulant heparin inhibits NF-B activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2000 278 Suppl H 2084-2093
36. Weiler J M., Edens R E., Linhardt R J., Kapelanski D P. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992 148 10 3210-3215
37. Geiben-Lynn R, Brown N, Walker B D., Luster A D. Purification of a modified form of bovine antithrombin III as an HIV-1 CD8 + T-cell antiviral factor. J Biol Chem 2002 277 44 42352-42357 (Pubitemid 35257556)
38. Ashikari-Hada S, Habuchi H, Kariya Y, Kimata K. Heparin regulates vascular endothelial growth factor 165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. J Biol Chem 2005 280 36 31508-31515 (Pubitemid 41291893)
39. Ono K, Hattori H, Takeshita S, Kurita A, Ishihara M. Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology 1999 9 7 705-711 (Pubitemid 29329014)
40. Wang L, Brown J R., Varki A, Esko J D. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002 110 1 127-136 (Pubitemid 34743473)
41. Wei M, Tai G, Gao Y et al. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J Biol Chem 2004 279 28 29202-29210 (Pubitemid 38915794)
42. O'Reilly M S., Pirie-Shepherd S, Lane W S., Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999 285 5435 1926-1928
43. Clowes A W., Karnowsky M J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977 265 5595 625-626 (Pubitemid 8034086)
44. Castellot J J. Jr, Favreau L V., Karnovsky M J., Rosenberg R D. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem 1982 257 19 11256-11260 (Pubitemid 13203358)
45. Gorelik E, Bere W W., Herberman R B. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer 1984 33 1 87-94 (Pubitemid 14223238)
46. Zhang W, Swanson R, Izaguirre G, Xiong Y, Lau L F., Olson S T. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 2005 106 5 1621-1628 (Pubitemid 41208574)
47. Ekman-Ordeberg G, Hellgren M, Akerud A et al. Low molecular weight heparin stimulates myometrial contractility and cervical remodeling in vitro. Acta Obstet Gynecol Scand 2009 88 9 984-989
48. Nikkila E. Studies on the lipid-protein relationship in normal and pathological sera and the effect of heparin on serum lipoproteins. Scand J Clin Lab Invest 1953 5 Suppl 8 9-100
49. Warkentin T E., Greinacher A, Koster A, Lincoff A M., American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008 133 6, Suppl 340S-380S (Pubitemid 351892970)
50. Walenga J M., Koza M J., Lewis B E., Pifarré R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996 2 Suppl 1 21-27
51. Walenga J M., Jeske W P., Prechel M M., Bacher P, Bakhos M. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin Thromb Hemost 2004 30 Suppl 1 69-80 (Pubitemid 38453585)
52. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995 74 3 886-892
53. Ahmad S, Haas S, Hoppensteadt D A. et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res 2002 108 1 49-55 (Pubitemid 36197662)
54. Untch B, Ahmad S, Jeske W P. et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thromb Res 2002 105 2 117-123 (Pubitemid 34214926)
55. Walenga J M., Adiguzel C, Iqbal O, Hoppensteadt D, Cunanan J, Bakhos M. Fibrin clot formation differs in the presence of branded and generic enoxaparins. J Thromb Haemost 2009 7 Suppl 2 Abstract PP-WE-387
56. Adiguzel C, Litinas E, Cunanan J, Hoppensteadt D, Walenga J M., Fareed J. Differential thrombin generation inhibition by branded and generic low molecular weight heparins (LMWHs) as studied by using fluorescence substrate based kinetic method. J Thromb Haemost 2009 7 Suppl 2 Abstract PP-MO-139
57. Walenga J M., Hoppensteadt D, Cunanan J, Jeske W P., Adiguzel C, Bakhos M. Immunogenicity of low molecular weight heparins and biosimilars. J Thromb Haemost 2009 7 Suppl 2 Abstract PP-MO-399
58. Kishimoto T K., Viswanathan K, Ganguly T et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008 358 23 2457-2467 (Pubitemid 351793019)